Methods for characterizing and treating acute myeloid leukemia

The invention features methods for characterizing and treating acute myeloid leukemia (AML) (e.g., newly diagnosed, relapsed, and refractory AML) in a subject using immunoconjugates of the invention. In one aspect, the invention generally features a method of treating acute myeloid leukemia in a subject (e.g., a human), the method involving administering an effective amount of an immunoconjugate to a pre-selected subject, where the immunoconjugate contains a humanized or chimeric antibody or fragment conjugated to a cytotoxic benzodiazepine dimer compound via a cleavable disulfide linker. 本发明的特征为使用本发明的免疫缀合物表征和治疗受试者中的急性髓样白血病(AML)(例如，新诊断、复发性和难治性AML)的方法。在个方面，本发明般特征在于治疗受试者(例如人)中的急性髓样白血病的方法，所述方法牵涉对预选受试者施用有效量的免疫缀合物，其中免疫缀合物含有经由可裂解的二硫化物接头与细胞毒性苯二氮杂二聚体化合物缀合的人源化或嵌合抗体或片段。